GLP-1 receptor agonists (semaglutide, tirzepatide, and the next generation behind them) shift glucose, lipids, inflammation, kidney function, and liver enzymes
Even further, protein and fiber are the two nutrients that, when combined, also promote delayed gastric emptying which keeps you fuller for longer and reduces appetite
Cardiovascular Outcome Trials in Type 2 Diabetes CVOTs in T2D were designed primarily to establish cardiovascular safety in patients diagnosed with T2D who also have established cardiovascular disease (CVD) or have a high cardiovascular risk
By multiple, we mean at least three, but many patients may have five or more (Laiteerapong N, Iveniuk J, John PM, Laumann EO, Huang ES
Dose escalation in the phase 3 trial is designed to reduce the incidence of gastrointestinal adverse events when switching to monthly dosing
At that time, there were no apparent neurological findings